Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cryo-Cell International ( (CCEL) ).
On March 9, 2026, Cryo-Cell International, Inc. received notice from NYSE American that it was not in compliance with continued listing standards due to a stockholders’ deficit as of Nov. 30, 2025 and net losses in two of its three most recent fiscal years. The company disclosed the notice in a March 12, 2026 press release and said its shares will continue to trade under the CCEL ticker while it works on a plan to regain compliance.
Cryo-Cell intends to submit a compliance plan by April 8, 2026, after which NYSE American may grant up to 18 months for the company to restore compliance, during which the stock remains listed if other requirements are met. The company cautioned that there is no assurance its plan will be accepted or that it will meet the standards in time, leaving investors exposed to the risk of potential delisting if compliance cannot be reestablished.
The most recent analyst rating on (CCEL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.
Spark’s Take on CCEL Stock
According to Spark, TipRanks’ AI Analyst, CCEL is a Neutral.
The score is primarily held back by weak financial quality (sharp revenue contraction, earnings volatility, and negative equity). Technicals are also slightly negative with the stock below key longer-term moving averages and a negative MACD. The main offset is the very high dividend yield, though the negative P/E limits valuation support.
To see Spark’s full report on CCEL stock, click here.
More about Cryo-Cell International
Cryo-Cell International, Inc., founded in 1989, is a pioneer in the stem cell banking industry and operates the world’s first private cord blood bank. The company provides private and public cord blood and cord tissue cryopreservation services, partners with Duke University on a public banking program, and offers advanced processing technology and biostorage solutions worldwide.
Cryo-Cell’s facility is FDA-registered, cGMP-/cGTP-compliant, licensed in all required U.S. states, and accredited by AABB and FACT for meeting stringent quality standards. Its public bank has supplied cord blood for more than 700 transplants and runs a donation site at Cedars–Sinai Hospital in Los Angeles, while the company also pursues cellular therapies and biopharmaceutical manufacturing initiatives.
Average Trading Volume: 12,382
Technical Sentiment Signal: Sell
Current Market Cap: $25.37M
For a thorough assessment of CCEL stock, go to TipRanks’ Stock Analysis page.